U.S. IVD Specimen Collection Devices Market: $7.08B by 2035

Market Outlook

By 2035, the U.S. IVD Specimen Collection Devices Market is expected to reach approximately USD 7.08 billion, expanding at a CAGR of 7.05% during the forecast period 2026–2035. The market is estimated at USD 3.58 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

The U.S. IVD specimen collection devices industry forms the critical pre-analytical foundation of the clinical diagnostics ecosystem. Every laboratory result begins with the quality of the specimen entering the testing workflow, making collection tubes, venipuncture devices, safety needles, lancets, swabs, urine containers, transport systems, stabilization products, capillary collection devices, saliva collection products, and other specimen-management consumables strategically important despite their relatively low unit prices. More than 14 billion laboratory tests are performed annually in the United States, creating one of the world’s largest recurring demand pools for diagnostic specimen acquisition and handling.

Unlike many capital-intensive IVD markets, specimen collection devices generate revenue predominantly through high-frequency recurring consumption. A blood collection tube, respiratory swab, urine container, stool collection kit, viral transport medium, or capillary collection device is generally used once, making test volume, patient encounters, screening intensity, and laboratory utilization stronger revenue determinants than installed-equipment cycles. This creates a resilient replacement profile across hospitals, physician offices, reference laboratories, urgent care centers, outpatient facilities, retail health settings, home collection programs, and public health laboratories.

Demand is increasingly shifting from basic collection consumables toward products that improve pre-analytical quality. U.S. laboratories and health systems are placing greater emphasis on correct fill volume, anticoagulant-to-blood ratios, hemolysis reduction, contamination prevention, sample stability, standardized labeling, safety-engineered sharps, closed urine collection, molecular-compatible transport, and integration with automated laboratory workflows. For suppliers, the commercial opportunity is moving from selling a tube, needle, or swab as an isolated commodity toward selling a specimen-quality platform that reduces redraws and protects downstream diagnostic accuracy.

The historical market expanded from an estimated USD 2.72 billion in 2021 to USD 3.35 billion in 2024. Early-period demand remained elevated in respiratory and infectious-disease specimen collection, while normalization of pandemic testing was progressively offset by recovery in routine laboratory volumes, chronic disease screening, outpatient diagnostics, molecular testing, oncology monitoring, women’s health testing, sexually transmitted infection screening, and hospital procedure activity. In 2025, the market reached approximately USD 3.58 billion, supported by higher diagnostic utilization and increased adoption of premium safety-engineered and capillary specimen collection technologies.

Introduction

According to the U.S. IVD Specimen Collection Devices Market Report, specimen acquisition is one of the most operationally consequential stages of the diagnostic pathway. Although analyzers, molecular platforms, immunoassay systems, and laboratory automation receive significant capital investment, the analytical result can only be as reliable as the biological sample supplied to the laboratory. Improper collection, inadequate volume, contamination, hemolysis, incorrect storage, unsuitable transport conditions, or patient-identification errors can create repeat draws, delayed diagnosis, unnecessary treatment decisions, and avoidable laboratory expense.

The market encompasses several distinct product ecosystems. Venous blood collection uses evacuated tubes, serum and plasma separators, EDTA tubes, citrate tubes, heparin tubes, needles, winged sets, tube holders, transfer devices, tourniquets, and specialized tubes for molecular or trace-element testing. Capillary collection includes lancets, microcollection tubes, absorbent collection devices, dried blood spot cards, and emerging low-volume collection systems. Non-blood specimen collection includes nasal and nasopharyngeal swabs, oral and buccal swabs, cervical and vaginal collection devices, urine cups and tubes, stool containers, saliva kits, specimen cards, microbiology transport systems, and nucleic-acid stabilization solutions.

The addressable market is supported by an unusually large U.S. diagnostic infrastructure. Laboratory testing is used across preventive care, chronic disease management, emergency medicine, inpatient care, surgical pathways, oncology, infectious disease, reproductive health, transplant medicine, toxicology, precision medicine, public health surveillance, and employer or occupational testing. Approximately 40% of primary-care encounters involve some form of medical testing, illustrating how deeply specimen collection is integrated into routine medical decision-making.

The industry is also influenced by labor economics. The United States employed more than 143,000 phlebotomists in 2025, in addition to nurses, medical assistants, laboratory technicians, respiratory clinicians, physicians, patients, and caregivers who collect specimens. Staffing shortages and workflow pressure make ease of use, first-stick success, pre-attached components, safety activation, specimen labeling, and reduced collection steps commercially meaningful. A product that saves only seconds per draw can create material operational value when deployed across millions of annual collection events.

From 2026 through 2035, the central strategic transformation will be the movement from traditional facility-based phlebotomy toward a mixed collection model combining hospital venipuncture, outpatient draw centers, retail collection, decentralized point-of-care testing, home collection, self-collected specimens, and microsampling. Manufacturers capable of maintaining laboratory-grade sample integrity while moving specimen acquisition closer to the patient will capture a growing share of market value.

Key Market Drivers: What’s Fueling the U.S. IVD Specimen Collection Devices Market Boom?

The first major driver is the sheer volume of U.S. diagnostic testing. More than 14 billion clinical laboratory tests are performed annually across the country, creating an enormous recurring requirement for consumable collection products. Routine chemistry, hematology, coagulation, immunology, microbiology, molecular diagnostics, pathology, toxicology, and genetic testing all rely on standardized specimen acquisition. Even modest growth in per-capita testing therefore creates substantial incremental demand for tubes, needles, swabs, cups, containers, and transport media.

The second major driver is the burden of chronic disease and the increasing frequency of longitudinal monitoring. More than 40 million Americans are estimated to have diabetes, while millions more have prediabetes, cardiovascular disease, kidney disease, thyroid disorders, cancer, autoimmune disease, and other chronic conditions requiring periodic laboratory assessment. Diabetes management alone creates recurring requirements for glucose, HbA1c, renal-function, lipid, and other blood testing. As the U.S. population ages and chronic conditions are managed for longer periods, specimen collection demand becomes increasingly recurring rather than episodic.

The third driver is continuing infectious-disease testing. Respiratory pathogens, sexually transmitted infections, urinary tract infections, gastrointestinal infections, bloodstream infections, and emerging infectious threats require diverse collection formats. More than 2.2 million reported U.S. cases of chlamydia, gonorrhea, and syphilis occurred in 2024, and recommended screening extends beyond symptomatic patients. Molecular diagnostics have also increased the importance of sample compatibility because nucleic-acid testing requires collection products that preserve target stability while minimizing inhibitory contaminants.

The fourth driver is increasing focus on pre-analytical quality. Diagnostic laboratories operate under intense pressure to reduce specimen rejection, redraw rates, contamination, labeling errors, and turnaround delays. Blood collection quality is especially important because incorrect fill volume, clotting, hemolysis, and tube selection can alter results or prevent testing entirely. Procurement departments increasingly recognize that the lowest-priced collection device may not have the lowest total cost when poor specimen quality causes repeat testing, staff rework, additional needle sticks, delayed discharge, or prolonged emergency-department decision times.

The fifth driver is healthcare worker safety. Traditional sharps expose phlebotomists, nurses, medical assistants, and laboratory staff to occupational needlestick risk. Safety-engineered needles, retractable blood collection sets, protected lancets, closed urine-transfer systems, integrated holders, and one-handed activation technologies are therefore becoming an important element of health-system standardization. Large U.S. hospitals increasingly evaluate specimen collection products not only on unit price but on employee safety, training burden, compliance, patient comfort, and consistency across facilities.

The sixth driver is decentralized diagnostics. Laboratory access is increasingly expanding into urgent care, retail health, employer clinics, pharmacy-adjacent settings, mobile care, home health, and patient-directed testing. The traditional assumption that a trained phlebotomist must collect every clinically useful diagnostic sample is being challenged by capillary blood collection, saliva testing, vaginal self-swabs, dried blood spots, urine self-collection, and other minimally invasive technologies. This shift is strategically important because it expands collection beyond the physical laboratory and can increase testing compliance among patients who face access barriers.

A seventh structural driver is reimbursement and home-based specimen economics. Medicare policies recognize eligible specimen collection services, and the general specimen collection fee increased to USD 9.34 in 2026, with a higher amount applicable in certain skilled nursing facility and home-health circumstances. Although device manufacturers are not directly reimbursed through these fees, the policy environment supports mobile and remote laboratory workflows where convenience and travel economics affect collection behavior. Over time, this will support products designed for home collection, specimen stabilization, transport durability, and simplified handling.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. IVD specimen collection devices market is increasingly directed toward making the pre-analytical process safer, less invasive, more standardized, and less dependent on highly trained labor. The next generation of products will compete on specimen quality and workflow economics rather than polymer type or container volume alone.

Capillary blood collection is one of the most strategically important innovation areas. Traditional finger-stick testing has generally been associated with small-volume point-of-care assays. New collection platforms are attempting to extend capillary sampling into central-laboratory testing by collecting sufficient low-volume specimens while maintaining analyte stability and standardization. In 2025, studies involving BD MiniDraw capillary technology demonstrated equivalence for selected commonly ordered tests compared with conventional venous collection, reinforcing the potential for retail and decentralized blood collection.

Needle-free and line-draw blood collection is another developing area. U.S. hospitals frequently collect blood from patients with existing peripheral intravenous lines, but conventional methods may create hemolysis, line disruption, or occupational exposure. New devices are designed to obtain laboratory specimens through vascular access systems while reducing unnecessary venipuncture. FDA clearance of newer needle-free blood collection products illustrates growing regulatory and commercial attention to this category.

Safety-engineered venipuncture continues to evolve through thinner needles, improved bevel geometries, push-button retraction, pre-attached holders, better flashback visualization, and integrated designs that reduce handling steps. These technologies are particularly important in oncology, pediatrics, geriatrics, emergency care, and other settings where patients may have fragile or difficult veins. Hospital value-analysis committees increasingly consider patient experience and first-stick success alongside worker safety.

Specimen preservation is also becoming a competitive differentiator. Molecular testing requires collection products that maintain nucleic-acid integrity, while microbiology requires appropriate organism preservation and transport conditions. Specialized stabilizing media can extend usable transport windows and support centralized testing from distant collection points. This becomes increasingly important as national reference laboratories receive specimens originating from retail sites, physician offices, remote communities, and patients’ homes.

Automation compatibility represents another innovation frontier. Modern high-volume laboratories are increasingly automated from sample receipt through centrifugation, decapping, aliquoting, sorting, storage, and analyzer loading. Collection devices must therefore meet dimensional, barcode, cap, fill-volume, and material requirements that function reliably within automation systems. Suppliers that design containers for both collection and downstream automated processing can reduce manual intervention and strengthen laboratory standardization.

Digital traceability will progressively influence the category. Barcode-enabled labels, pre-labeled collection kits, electronic test-order integration, positive patient identification, and chain-of-custody workflows can reduce mismatch risk. In toxicology, genetics, transplant testing, clinical trials, and high-complexity diagnostics, the value of the specimen often exceeds the value of the collection device by several orders of magnitude. Traceability is therefore becoming an important part of premium specimen-management offerings.

Segmentation Insights

The U.S. IVD Specimen Collection Devices Market is segmented on the basis of product type, specimen type, application, end user, and region.

By Product Type

Blood collection tubes and microcollection containers represent the largest product category by value. This segment includes serum-separation tubes, plasma-separation tubes, EDTA tubes, sodium citrate tubes, heparin tubes, fluoride/oxalate tubes, specialty molecular tubes, pediatric microtainers, capillary tubes, and other evacuated or non-evacuated formats. Revenue is supported by enormous routine testing volumes across chemistry, hematology, coagulation, immunoassay, molecular diagnostics, and therapeutic monitoring. Premium growth is occurring in tubes designed to shorten processing time, improve plasma quality, stabilize specialized analytes, or reduce pre-analytical variability.
Needles, blood collection sets, holders, and lancets form another major recurring segment. Straight needles remain widely used in high-throughput phlebotomy, while winged collection sets are important for difficult venous access. Safety activation, retractable needles, pre-attached holders, improved patient comfort, and smaller-gauge designs provide opportunities for premium differentiation. Capillary lancets are gaining strategic importance because decentralized and patient-centric testing models rely on standardized finger-stick acquisition.
Swabs and microbiological collection systems are a major non-blood product category. Nasal, nasopharyngeal, throat, buccal, oral, cervical, vaginal, wound, and environmental swabs are used across respiratory testing, sexually transmitted infection testing, molecular diagnostics, culture, genomic analysis, and public-health surveillance. Demand has normalized from pandemic peaks but remains structurally above pre-2020 levels because molecular testing infrastructure and clinical familiarity with swab-based diagnostics have expanded.
Urine, stool, saliva, and other specimen containers provide a broad recurring revenue base across urinalysis, microbiology, toxicology, pregnancy testing, sexually transmitted infection testing, gastrointestinal diagnostics, molecular assays, hormone testing, and genetic applications. Closed urine-transfer systems, leak-resistant containers, preservative tubes, and standardized collection kits are gaining adoption where laboratories seek to reduce contamination and improve transport reliability.
Transport, stabilization, collection-card, and specialty devices are expected to be among the fastest-growing product categories. This segment includes viral and universal transport systems, molecular stabilization products, dried blood spot cards, absorbent matrices, saliva stabilization systems, specialty genetic collection kits, and temperature-tolerant transport solutions. Growth is linked to decentralized diagnostics, reference-laboratory testing, clinical trials, newborn screening, genomics, and home specimen collection.

By Specimen Type

Blood specimens account for the largest share of the U.S. IVD specimen collection devices market. Blood remains the principal diagnostic specimen for chemistry, hematology, coagulation, serology, immunology, endocrinology, oncology, infectious-disease testing, therapeutic drug monitoring, and many molecular tests. Venous collection dominates conventional laboratory volumes, but capillary blood is expected to grow faster through 2035 as microsampling technologies improve and lower-volume testing becomes more standardized.
Respiratory and oral specimens represent an important molecular-diagnostics segment. Nasal and nasopharyngeal specimens remain central to influenza, SARS-CoV-2, RSV, and other respiratory testing. Throat and oral specimens are used across infectious disease and molecular workflows. The commercial focus has shifted from emergency pandemic procurement toward reliable routine supply, seasonal surge capacity, multiplex respiratory panels, and simplified collection.
Urine specimens generate substantial recurring demand across urinalysis, urinary tract infection testing, pregnancy testing, toxicology, sexually transmitted infection testing, renal assessment, and occupational screening. Market value is shifting toward leak-resistant cups, integrated transfer devices, preservative tubes, vacuum transfer systems, and solutions designed to reduce healthcare-worker contact with open specimens.
Stool specimens are increasingly important in gastrointestinal pathogen detection, colorectal cancer screening, microbiome applications, inflammatory bowel disease assessment, and other gastrointestinal diagnostics. Molecular gastrointestinal panels require reliable transport and compatible preservatives. At-home colorectal screening programs also create opportunities for consumer-friendly collection designs with clear instructions and mail-compatible packaging.
Saliva, buccal, vaginal, cervical, and specialty specimens represent the fastest-expanding specimen group. These formats support genomics, reproductive health, HPV testing, sexually transmitted infection diagnostics, hormone testing, pharmacogenomics, infectious-disease screening, and consumer-initiated testing. Self-collection can reduce embarrassment, travel requirements, clinician time, and access barriers, making these specimens highly relevant to decentralized healthcare.

By Application

Routine clinical chemistry, hematology, and coagulation testing remain the largest application group because they generate consistently high blood collection volumes. Complete blood counts, metabolic panels, lipid testing, thyroid studies, liver and kidney assessment, coagulation monitoring, and other routine laboratory investigations are embedded throughout U.S. healthcare. This segment is relatively mature but highly resilient because collection products are single-use and tied directly to patient encounters.
Infectious disease and microbiology form a higher-growth application segment. Blood cultures, respiratory panels, sexually transmitted infection testing, gastrointestinal testing, wound cultures, urinary cultures, and molecular pathogen detection require a broad range of collection and transport products. Specimen quality is particularly important because contamination or insufficient organism recovery can materially alter clinical interpretation.
Chronic disease screening and monitoring is strategically important because it creates recurring collection frequency across diabetes, kidney disease, cardiovascular risk, thyroid disorders, autoimmune disease, and other long-term conditions. As U.S. healthcare shifts toward preventive management and quality metrics, diagnostic testing is increasingly used to identify deterioration before hospitalization. Collection suppliers benefit from this recurring testing cycle without depending on a single disease category.
Oncology, genomic, and molecular testing represent premium applications where specimen quality requirements are high. Molecular assays may depend on precise tube chemistry, DNA or RNA stabilization, controlled transport, and strict chain-of-custody. Although volumes are lower than routine chemistry, average collection-product value can be substantially higher because specialty preservatives, collection kits, and transport materials are used.
Women’s health, reproductive health, toxicology, and specialty testing create additional growth opportunities. Vaginal and cervical self-collection, pregnancy-related testing, fertility evaluation, STI screening, drug testing, employer screening, and forensic applications require purpose-designed collection systems. These markets favor products that combine simple instructions with tamper evidence, patient privacy, transport stability, and accurate specimen identification.

By End User

Hospitals and integrated health systems are the largest institutional purchasers. Hospitals consume specimen collection products across emergency departments, inpatient units, intensive care, surgery, oncology, labor and delivery, outpatient departments, and hospital-owned physician networks. Large health systems typically standardize a limited number of vendors through enterprise contracts and group purchasing arrangements. Winning these accounts requires supply reliability, clinical evidence, staff training, contracting flexibility, and compatibility with laboratory automation.
Independent and reference laboratories represent another major end-user group. High-volume national and regional laboratories depend on standardized collection kits distributed across physician offices, patient service centers, employer sites, and remote collection locations. Their purchasing priorities include specimen stability, transport durability, barcode consistency, automation compatibility, standardized packaging, and low rejection rates. Because specimens may travel long distances, collection quality is directly connected to central-laboratory productivity.
Physician offices, urgent care centers, and outpatient clinics generate significant demand for tubes, needles, swabs, urine products, and point-of-care-compatible collection devices. These settings generally have smaller inventories and less specialized laboratory staff than major hospitals. Products that are intuitive, compact, preassembled, and easy to store have an advantage. Continued migration of diagnostics toward ambulatory care will expand this customer base.
Retail, home-health, mobile, and decentralized collection providers are expected to grow fastest through 2035. This segment includes home phlebotomy, mobile laboratory services, retail collection locations, decentralized chronic disease programs, clinical-trial home sampling, direct-to-consumer testing, and patient self-collection. Traditional venipuncture will remain important, but future growth will increasingly come from microsampling, dried blood, saliva, urine, and self-swab technologies.
Academic, public health, pharmaceutical, and research laboratories represent a smaller but strategically valuable segment. Clinical trials, biobanking, epidemiology, translational research, genomic studies, and public health surveillance require standardized collection protocols and may use specialized tubes, stabilization reagents, transport systems, and specimen cards. These users often influence future clinical adoption because collection methods validated in research can migrate into routine diagnostics.

Regional Insights: Where the Market Is Growing Fastest

The U.S. IVD Specimen Collection Devices Market is geographically divided into the South, West, Northeast, and Midwest. Regional demand is determined by population size, population growth, age profile, chronic disease burden, hospital and laboratory density, outpatient diagnostic utilization, academic research activity, reference-laboratory infrastructure, and adoption of decentralized testing.

The South represents the largest regional market, while the West is expected to record the strongest percentage growth through 2035. The Northeast remains a high-value region for complex diagnostics and academic laboratory activity, while the Midwest provides a large, stable base of hospital and reference-laboratory consumption.

South

The South accounted for an estimated USD 1.29 billion in 2025, representing approximately 36% of U.S. market value. The region includes Texas, Florida, Georgia, North Carolina, Tennessee, South Carolina, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, Virginia, Maryland, and West Virginia within the commercial geography used in this report.

The South has the strongest underlying demographic expansion of the four U.S. regions. Population growth supports laboratory demand through additional physician encounters, hospital admissions, outpatient procedures, preventive testing, maternity care, infectious-disease testing, and chronic disease monitoring. Texas, Florida, North Carolina, Georgia, South Carolina, and Tennessee are particularly important because they combine population gains with expanding health-system infrastructure.

Texas is one of the largest individual state opportunities. Its population exceeded 31.7 million in 2025, with large healthcare and laboratory ecosystems concentrated around Houston, Dallas-Fort Worth, Austin, and San Antonio. The state supports high-volume demand across hospital phlebotomy, oncology, infectious disease, toxicology, women’s health, and reference-laboratory services. Large distances between communities also create opportunities for transport-stable and decentralized specimen collection.

Florida is another major demand center, with a 2025 population exceeding 23.4 million and a particularly large older population. Its demographic profile supports frequent chemistry, hematology, cardiovascular risk, oncology, renal, endocrine, and medication-monitoring tests. Florida is also attractive for home phlebotomy and mobile collection because older adults frequently require recurring laboratory monitoring.

Georgia and North Carolina are increasingly important commercial markets. Both states have populations above 11 million and substantial metropolitan expansion. Atlanta is a major health-system, logistics, and public-health hub, while North Carolina combines large health systems with strong academic medicine, biotechnology, pharmaceutical development, and clinical research activity. These characteristics support both routine collection consumables and higher-value specialty specimen kits.

Virginia, Maryland, Tennessee, and South Carolina offer attractive growth across hospital networks, molecular diagnostics, government-related healthcare, university systems, and outpatient testing. Maryland’s proximity to federal health research infrastructure gives the market significance beyond its population size, while Tennessee includes major healthcare corporate activity and large laboratory and provider organizations.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia are smaller device markets individually but collectively provide a substantial chronic-disease testing pool. Rural access challenges can make decentralized collection particularly valuable. Mobile phlebotomy, home collection, specimen stabilization, and shipment-ready kits can improve testing access where patients live far from major laboratories.

By 2035, the South is projected to reach approximately USD 2.66 billion, representing an estimated regional CAGR of about 7.5%. The region should remain the largest U.S. opportunity because population growth and diagnostic infrastructure expansion reinforce recurring consumption.

West

The West generated an estimated USD 0.84 billion in 2025 and is forecast to be the fastest-growing regional market. The region includes California, Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the largest state market in the West and one of the most important U.S. specimen collection markets overall. With more than 39 million residents, California combines extraordinary testing volume with academic medicine, biotechnology, genomics, digital health, diagnostic innovation, and large integrated delivery networks. The state is a significant early market for home specimen collection, decentralized molecular testing, reproductive diagnostics, genomic collection kits, and patient-directed testing models.

California also has a diverse healthcare delivery structure ranging from major academic centers to large integrated systems, physician networks, community clinics, retail healthcare, public health programs, and research laboratories. This breadth creates demand across virtually every specimen type. Manufacturers often use California as an early commercialization environment for products that combine collection devices with digital ordering, consumer engagement, and logistics.

Arizona and Nevada benefit from population growth and aging demographics. Arizona’s older population creates recurring testing demand for diabetes, cardiovascular disease, kidney disease, oncology, and medication monitoring. Phoenix is also becoming an increasingly important healthcare and diagnostics hub. Nevada is smaller but growing and provides attractive outpatient and retail testing opportunities around Las Vegas and Reno.

Washington, Oregon, Colorado, and Utah are particularly relevant for digital-health-enabled diagnostics and integrated care models. Provider organizations in these states have strong experience with virtual care and centralized health-system operations. Home specimen collection and patient-centric sampling fit well with these care models, particularly for chronic disease monitoring, clinical trials, genetic testing, and preventive screening.

Idaho, Montana, Wyoming, New Mexico, Alaska, and Hawaii represent smaller state markets but demonstrate the strategic need for transport stability and decentralized collection. Geographic distance can make centralized phlebotomy inconvenient. Products that remain analytically stable during shipment and can be collected outside major hospitals have stronger long-term potential in these states.

The West is projected to expand to approximately USD 1.79 billion by 2035, reflecting a regional CAGR of approximately 7.9%. Its growth advantage is expected to come less from conventional venipuncture alone and more from microsampling, molecular collection, self-collection, genomics, and digitally coordinated laboratory services.

Northeast

The Northeast accounted for approximately USD 0.78 billion in 2025. For commercial purposes, this report includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Delaware, Maine, Vermont, New Hampshire, and Rhode Island.

The region is characterized by dense healthcare infrastructure, a high concentration of academic medical centers, established reference laboratories, advanced oncology programs, biotechnology, pharmaceutical research, and significant diagnostic sophistication. Population growth is slower than in the South, but testing intensity per patient and the complexity of diagnostic workflows are comparatively high.

New York is the largest market in the Northeast. New York State had approximately 20 million residents in 2025, with enormous laboratory demand centered around New York City and other urban regions. Hospital systems, physician networks, oncology programs, women’s health, transplant medicine, infectious disease services, and high-complexity laboratories generate significant demand for blood, urine, swab, microbiology, and specialty molecular collection products.

Pennsylvania and New Jersey form another important testing corridor. Pennsylvania combines large metropolitan health systems in Philadelphia and Pittsburgh with major community-hospital networks. New Jersey has a dense pharmaceutical and life-sciences ecosystem in addition to significant hospital and laboratory activity. The two states support strong demand for clinical trial collection, central-laboratory kits, genomics, and routine diagnostic consumables.

Massachusetts is commercially influential despite its smaller population because of the concentration of academic medicine, biotechnology, genomic research, clinical trials, and advanced diagnostics around Boston and Cambridge. Specialty specimen stabilization products, collection kits for molecular testing, and research-grade systems can achieve disproportionate adoption in this market.

Connecticut, Rhode Island, New Hampshire, Vermont, Maine, and Delaware provide smaller but attractive markets supported by regional health systems, aging populations, and outpatient diagnostic utilization. New England’s older population profile supports recurring routine blood testing, while long travel distances in parts of Maine, Vermont, and New Hampshire can strengthen the value proposition for home collection.

The Northeast is expected to reach approximately USD 1.41 billion by 2035. Growth will be slower than in the South and West because the provider market is mature, but the region should retain above-average value per collection event because of specialty diagnostics, academic testing, clinical research, and complex laboratory workflows.

Midwest

The Midwest represented approximately USD 0.67 billion in 2025. The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

The Midwest provides a stable demand base built around large hospital systems, regional reference laboratories, chronic disease testing, community healthcare networks, medical technology companies, and major academic institutions. The market has less population growth than the South but relatively dependable testing utilization.

Illinois is the largest Midwestern market. Chicago supports major academic health systems, independent laboratories, physician networks, oncology programs, and a large urban patient population. The state generates substantial recurring demand for blood tubes, safety needles, swabs, urine products, microbiology transport systems, and specialty collection devices.

Ohio and Michigan are large markets supported by high hospital density, extensive outpatient care, established reference networks, and chronic disease burden. Cleveland, Columbus, Cincinnati, Detroit, and Ann Arbor are important diagnostic centers. Health systems in these states tend to emphasize standardized contracting, predictable supply, staff training, and cost control, favoring manufacturers that can demonstrate reliability at scale.

Minnesota has strategic importance because of its medtech ecosystem, sophisticated provider organizations, and strong laboratory infrastructure. Although population is smaller than Illinois or Ohio, the state is an influential environment for healthcare innovation and procurement.

Indiana, Wisconsin, and Missouri offer substantial hospital and laboratory consumption, while Iowa, Kansas, Nebraska, North Dakota, and South Dakota provide opportunities around regional referral networks and rural diagnostics. Home collection and transport-stable sampling systems are especially relevant where laboratories serve patients across large geographic catchment areas.

The Midwest is projected to reach approximately USD 1.22 billion by 2035, representing steady growth of approximately 6.2% annually. The market will remain highly attractive for suppliers with broad portfolios, dependable domestic distribution, competitive enterprise contracting, and strong technical support.

Key Market Players

The U.S. IVD Specimen Collection Devices Competitive Landscape is moderately consolidated in high-volume blood collection, while non-blood collection and decentralized sampling remain more fragmented. BD maintains exceptional scale in blood and urine specimen management, but Greiner Bio-One and SARSTEDT provide major international competition. Swab and transport markets include specialized companies such as COPAN and Puritan, while capillary and home sampling are attracting newer technology companies.

Competitive differentiation is increasingly based on full-workflow value. Large manufacturers can combine blood collection tubes, needles, urine collection, safety products, automation compatibility, training, logistics, and enterprise contracts. Specialized companies compete through molecular compatibility, proprietary swab design, patient self-collection, microsampling, specimen stabilization, or low-volume blood acquisition.

Some of the key players in the U.S. IVD Specimen Collection Devices industry are:

Becton, Dickinson and Company
Greiner Bio-One International
SARSTEDT AG & Co. KG
Cardinal Health
Medline Industries
McKesson Medical-Surgical
Thermo Fisher Scientific
COPAN Diagnostics
Puritan Medical Products
Hardy Diagnostics
QIAGEN
OraSure Technologies
DNA Genotek
Terumo Medical Corporation
Nipro Medical Corporation
Sol-Millennium Medical
Retractable Technologies
Owen Mumford
Tasso, Inc.
Babson Diagnostics
Trajan Scientific and Medical
Neoteryx
Spot On Sciences
Mawi DNA Technologies

BD, Greiner Bio-One, and SARSTEDT are the most important competitors in conventional blood specimen collection because of broad tube and phlebotomy portfolios, established laboratory relationships, and large-scale manufacturing. Cardinal Health, Medline, and McKesson influence market access through distribution and private-label procurement. COPAN, Puritan, and Hardy are important in microbiology and swab-based specimen collection.

QIAGEN, OraSure, DNA Genotek, Mawi DNA Technologies, Neoteryx, Tasso, Spot On Sciences, Babson Diagnostics, and related innovators are important because the future market will increasingly include self-collection, genomics, saliva, dried blood, low-volume sampling, and remote diagnostic workflows.

Market-share gains through 2035 will depend on more than price. Suppliers will need to demonstrate supply continuity, automation compatibility, sample integrity, patient comfort, sharps safety, assay compatibility, transport stability, clinical evidence, and measurable reductions in redraws or operational labor. Companies capable of integrating collection into broader diagnostic and digital ecosystems will have an advantage over suppliers selling undifferentiated consumables.

Recent Developments

Recent developments in the U.S. IVD specimen collection devices market show a clear movement toward less invasive and more decentralized blood collection. In March 2025, BD and Babson Diagnostics reported new study results involving the BD MiniDraw capillary blood collection technology, showing that selected commonly used wellness and chronic-disease laboratory tests could generate results comparable with conventional venous sampling. The development is commercially important because it supports collection in locations that do not require conventional venipuncture infrastructure.

FDA activity is also demonstrating continued innovation in blood specimen acquisition. In May 2025, the FDA determined the Navi Needle-free Blood Collection Device to be substantially equivalent through the 510(k) pathway. Technologies of this type are designed around obtaining diagnostic blood specimens while reducing dependence on additional needle sticks, highlighting growing competition around patient comfort and workflow efficiency.

In April 2026, the FDA issued a substantially equivalent decision for updated BD Vacutainer Safety-Lok blood collection sets. Continued regulatory activity in a seemingly mature category shows that safety engineering, device configuration, usability, and integration remain active areas of innovation even in conventional venipuncture.

Capillary and self-collection technologies are also moving closer to mainstream laboratory workflows. The commercial challenge is no longer simply whether a small specimen can be obtained. The more important issue is whether that specimen remains analytically equivalent through collection, transport, processing, storage, and testing. Manufacturers that generate evidence across the full pre-analytical pathway are more likely to achieve acceptance among reference laboratories and health systems.

Another development is the broader use of specimen collection outside traditional laboratories. Home health, clinical trials, telehealth-supported testing, retail diagnostics, and direct-access laboratory services are increasing demand for collection products that patients or minimally trained staff can use correctly. This trend is creating opportunities for prepackaged kits, simplified instructions, dried specimens, saliva stabilization, patient-friendly capillary sampling, and ambient-stable transport.

The industry is simultaneously becoming more sensitive to supply-chain resilience. Hospitals and reference laboratories experienced significant disruption in collection consumables during the pandemic era, increasing procurement attention to domestic manufacturing, secondary sourcing, distributor inventory, and alternative product qualification. Vendors able to guarantee continuity during seasonal respiratory surges or unexpected outbreaks can secure strategic preferred-supplier status even when they are not the lowest-priced bidder.

Conclusion

The U.S. IVD Specimen Collection Devices Market Size & Share is positioned to increase from approximately USD 3.58 billion in 2025 to USD 7.08 billion by 2035, representing a 7.05% CAGR during 2026–2035. The market is supported by the extraordinary scale of U.S. laboratory testing, chronic disease monitoring, infectious-disease screening, recurring consumable use, healthcare worker safety requirements, and expansion of decentralized diagnostics.

The most important strategic opportunity is not conventional unit growth alone. Value creation is moving toward premium specimen-management products that solve pre-analytical problems. Safety-engineered venipuncture, capillary blood collection, self-collected specimens, molecular stabilization, transport media, closed urine systems, automation-compatible containers, and digitally traceable collection kits are likely to outperform undifferentiated commodity products.

Blood collection will remain the largest specimen category because routine chemistry, hematology, coagulation, immunology, and chronic disease monitoring generate enormous recurring volumes. However, saliva, self-swabs, dried blood, low-volume capillary sampling, vaginal collection, and specialty molecular specimens will expand faster because these formats enable testing outside conventional laboratory environments.

Hospitals and reference laboratories will remain the most commercially important buyers, but future growth will increasingly come from ambulatory care, retail collection, mobile phlebotomy, home health, patient self-collection, clinical trials, and digital diagnostic pathways. This creates a strategic requirement for manufacturers to design products around both analytical performance and user experience.

Regional opportunity will be led by the South, which is expected to increase from approximately USD 1.29 billion in 2025 to USD 2.66 billion by 2035 as population and healthcare infrastructure expand. The West will provide the fastest growth through patient-centric diagnostics and technology adoption. The Northeast will remain highly attractive for molecular diagnostics, clinical research, and advanced laboratory testing, while the Midwest will provide stable high-volume demand and strong integrated health-system procurement.

At the state level, California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, New Jersey, Massachusetts, Washington, Arizona, Virginia, Tennessee, and Minnesota will be particularly important to suppliers because they combine population scale, testing intensity, health-system concentration, laboratory infrastructure, or innovation adoption.

For companies evaluating the U.S. IVD specimen collection devices industry, the central question is no longer whether the United States will require more specimen collection products. The more commercially important questions are which collection workflows will shift outside hospitals, which technologies can reduce pre-analytical error, which products can function reliably in decentralized care, and which suppliers can prove a lower total cost per valid laboratory result.

The manufacturers that define the next decade will therefore be those that treat specimen collection not as a low-value disposable category but as the first quality-control step in the diagnostic process. Products that improve sample integrity, protect healthcare workers, reduce patient discomfort, enable collection closer to the patient, and preserve specimens through increasingly complex laboratory networks will capture a disproportionate share of U.S. market growth.

TABLE OF CONTENT

1. U.S. IVD Specimen Collection Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. IVD Specimen Collection Device Manufacturers
1.6.2. Raw Material, Component and Contract Manufacturing Suppliers
1.6.3. Hospitals and Integrated Delivery Networks
1.6.4. Independent and Reference Laboratories
1.6.5. Physician Offices, Urgent Care Centers and Outpatient Clinics
1.6.6. Group Purchasing Organizations, Distributors and Specialty Suppliers
1.6.7. Regulators, Payers, Laboratory Directors and Clinical Decision-Makers

What this section provides: This section defines the market boundary, inclusion and exclusion criteria, methodology, assumptions, and stakeholder ecosystem so clients understand how the U.S. IVD specimen collection devices market is measured, validated, and forecast.

2. U.S. IVD Specimen Collection Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.8. Pre-Analytical Workflow Transformation Snapshot
2.9. Decentralized and Self-Collection Opportunity Assessment

What this section provides: This section gives decision-makers a concise view of market size, historical development, forecast direction, major specimen collection demand pools, competitive intensity, and high-priority commercial opportunities.

3. U.S. IVD Specimen Collection Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. High Volume of Clinical Laboratory Testing Across the U.S.
3.1.2. Rising Chronic Disease Screening and Monitoring Requirements
3.1.3. Expansion of Molecular and Infectious Disease Diagnostics
3.1.4. Increasing Focus on Pre-Analytical Specimen Quality
3.1.5. Growing Adoption of Safety-Engineered Blood Collection Devices
3.1.6. Expansion of Home, Retail and Decentralized Specimen Collection
3.1.7. Rising Demand for Patient-Centric and Low-Volume Sampling
3.2. Restraints and Their Impact Analysis
3.2.1. Commodity Pricing Pressure in Conventional Collection Products
3.2.2. GPO and Integrated Health System Purchasing Concentration
3.2.3. Specimen Rejection, Hemolysis and Pre-Analytical Error Risk
3.2.4. Regulatory and Clinical Validation Requirements
3.2.5. Interoperability Limitations Across Laboratory Automation Platforms
3.2.6. Adoption Barriers for Patient Self-Collection
3.3. Opportunities and Their Impact Analysis
3.3.1. Capillary Blood Collection and Microsampling
3.3.2. Home-Based and Patient Self-Collection
3.3.3. Molecular Specimen Stabilization and Ambient Transport
3.3.4. Needle-Free and Peripheral IV Blood Collection
3.3.5. Automated Specimen Identification and Digital Traceability
3.3.6. Specialty Collection for Genomics and Precision Medicine
3.3.7. Clinical Trial and Decentralized Research Collection Kits
3.4. Challenges and Their Impact Analysis
3.4.1. Maintaining Analytical Equivalence Across Alternative Collection Methods
3.4.2. Standardization Across Hospital and Laboratory Networks
3.4.3. Healthcare Workforce Training and Collection Compliance
3.4.4. Supply Chain Continuity for High-Volume Disposable Products
3.4.5. Specimen Transportation and Stability Challenges
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Pre-Analytical Clinical Workflow Economics Analysis
3.7. Hospital and Laboratory Procurement Behavior Analysis
3.8. Specimen Quality and Laboratory Rejection Economics
3.9. Decentralized Testing Impact on Collection Workflows

What this section provides: This section analyzes the clinical, operational, regulatory, procurement, and economic forces shaping specimen collection demand and helps clients evaluate market upside, adoption barriers, and execution risks.

4. U.S. IVD Specimen Collection Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Raw Material and Manufacturing Landscape
4.6. Impact of Laboratory Automation and Digitalization
4.7. Application & Innovation Landscape
4.8. FDA Regulatory Framework Analysis
4.9. CLIA and Laboratory Quality Framework
4.10. CMS Reimbursement and Specimen Collection Payment Landscape
4.11. OSHA Sharps Safety and Healthcare Worker Protection Landscape
4.12. Import/Export Restrictions & Tariff Impact
4.13. Government Initiatives and Public Health Testing Programs
4.14. Impact of Escalating Geopolitical Tensions
4.15. Hospital and Laboratory Value Analysis Committee Decision Framework
4.16. GPO Contracting and Vendor Standardization Analysis

What this section provides: This section gives clients a comprehensive view of the regulatory, laboratory-quality, reimbursement, pricing, supply-chain, safety, technology, and procurement environment influencing the U.S. IVD specimen collection devices industry.

5. U.S. IVD Specimen Collection Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.2. Blood Collection Tubes and Microcollection Containers
5.2.1. Serum Collection Tubes
5.2.2. Plasma Collection Tubes
5.2.3. EDTA Tubes
5.2.4. Sodium Citrate Tubes
5.2.5. Heparin Tubes
5.2.6. Fluoride/Oxalate Tubes
5.2.7. Serum and Plasma Separation Tubes
5.2.8. Molecular and Specialty Collection Tubes
5.2.9. Capillary and Microcollection Tubes
5.3. Needles, Blood Collection Sets, Holders and Lancets
5.3.1. Multi-Sample Blood Collection Needles
5.3.2. Winged Blood Collection Sets
5.3.3. Safety-Engineered Needles
5.3.4. Blood Collection Tube Holders
5.3.5. Safety Lancets
5.3.6. Capillary Sampling Devices
5.3.7. Needle-Free Blood Collection Devices
5.4. Swabs and Microbiological Collection Systems
5.4.1. Nasal Swabs
5.4.2. Nasopharyngeal Swabs
5.4.3. Throat and Oral Swabs
5.4.4. Buccal Swabs
5.4.5. Cervical and Vaginal Swabs
5.4.6. Wound and Microbiology Swabs
5.4.7. Flocked Swab Collection Systems
5.5. Urine, Stool, Saliva and Other Specimen Containers
5.5.1. Urine Collection Cups and Containers
5.5.2. Vacuum Urine Collection and Transfer Systems
5.5.3. Urine Preservation Tubes
5.5.4. Stool Collection Containers
5.5.5. Saliva Collection Devices
5.5.6. Specialty Biological Specimen Containers
5.6. Transport, Stabilization, Collection Cards and Specialty Devices
5.6.1. Viral Transport Media
5.6.2. Universal Transport Media
5.6.3. Microbiology Transport Systems
5.6.4. DNA/RNA Stabilization Systems
5.6.5. Dried Blood Spot Cards
5.6.6. Absorbent Microsampling Devices
5.6.7. Genomic and Molecular Collection Kits
5.6.8. Home Specimen Collection Kits
5.6.9. Other Specialty Specimen Collection Devices

What this section provides: This section identifies the specimen collection product categories generating the largest revenue contribution and highlights premium-growth opportunities in safety devices, microsampling, molecular stabilization, and decentralized collection.

6. U.S. IVD Specimen Collection Devices Market – By Specimen Type

6.1. Overview
6.1.1. Segment Share Analysis, By Specimen Type, 2025 & 2035 (%)
6.2. Blood
6.2.1. Venous Blood
6.2.2. Capillary Blood
6.2.3. Arterial Blood
6.2.4. Whole Blood
6.2.5. Serum
6.2.6. Plasma
6.3. Respiratory Specimens
6.3.1. Nasal Specimens
6.3.2. Nasopharyngeal Specimens
6.3.3. Oropharyngeal Specimens
6.3.4. Other Respiratory Specimens
6.4. Urine
6.4.1. Routine Urinalysis Specimens
6.4.2. Microbiology Urine Specimens
6.4.3. Toxicology Urine Specimens
6.4.4. Molecular Testing Urine Specimens
6.5. Stool
6.5.1. Gastrointestinal Infectious Disease Specimens
6.5.2. Colorectal Screening Specimens
6.5.3. Gastrointestinal Biomarker Specimens
6.5.4. Molecular and Microbiome Specimens
6.6. Saliva, Buccal, Genital and Other Specialty Specimens
6.6.1. Saliva
6.6.2. Buccal Specimens
6.6.3. Vaginal Specimens
6.6.4. Cervical Specimens
6.6.5. Wound Specimens
6.6.6. Other Specialty Specimens

What this section provides: This section evaluates demand by biological specimen and highlights how venous blood remains dominant while capillary, saliva, genital, and other self-collectable specimens gain importance through 2035.

7. U.S. IVD Specimen Collection Devices Market – By Application

7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
7.2. Routine Clinical Chemistry, Hematology and Coagulation
7.2.1. Clinical Chemistry Testing
7.2.2. Hematology Testing
7.2.3. Coagulation Testing
7.2.4. Immunochemistry and Serology Testing
7.3. Infectious Disease and Microbiology
7.3.1. Respiratory Infectious Disease Testing
7.3.2. Sexually Transmitted Infection Testing
7.3.3. Urinary Tract Infection Testing
7.3.4. Gastrointestinal Infection Testing
7.3.5. Bloodstream Infection Testing
7.3.6. Wound and Other Microbiology Testing
7.4. Chronic Disease Screening and Monitoring
7.4.1. Diabetes Monitoring
7.4.2. Cardiovascular Risk Testing
7.4.3. Renal Disease Monitoring
7.4.4. Thyroid and Endocrine Testing
7.4.5. Autoimmune and Inflammatory Disease Testing
7.5. Oncology, Genomic and Molecular Testing
7.5.1. Oncology Biomarker Testing
7.5.2. Molecular Diagnostics
7.5.3. Genetic and Genomic Testing
7.5.4. Pharmacogenomic Testing
7.5.5. Precision Medicine Applications
7.6. Women’s Health, Reproductive Health, Toxicology and Specialty Testing
7.6.1. Women’s Health Testing
7.6.2. Reproductive and Fertility Testing
7.6.3. Prenatal Testing
7.6.4. Toxicology and Drug Testing
7.6.5. Occupational and Employer Screening
7.6.6. Clinical Trial and Research Testing

What this section provides: This section identifies the diagnostic applications generating specimen collection demand and highlights applications where testing frequency, molecular adoption, screening programs, and chronic disease monitoring create attractive growth opportunities.

8. U.S. IVD Specimen Collection Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.2. Hospitals and Integrated Health Systems
8.2.1. Academic Medical Centers
8.2.2. Community Hospitals
8.2.3. Hospital Outpatient Departments
8.2.4. Emergency and Acute Care Settings
8.3. Independent and Reference Laboratories
8.3.1. National Reference Laboratories
8.3.2. Regional Reference Laboratories
8.3.3. Independent Clinical Laboratories
8.3.4. Patient Service Centers
8.4. Physician Offices, Urgent Care Centers and Outpatient Clinics
8.4.1. Physician Office Laboratories
8.4.2. Urgent Care Centers
8.4.3. Specialty Clinics
8.4.4. Community Health Centers
8.5. Retail, Home Health, Mobile and Decentralized Collection Providers
8.5.1. Retail Diagnostic Collection Sites
8.5.2. Mobile Phlebotomy Providers
8.5.3. Home Healthcare Providers
8.5.4. Patient Self-Collection Programs
8.5.5. Direct-to-Consumer Diagnostic Providers
8.6. Academic, Public Health, Pharmaceutical and Research Laboratories
8.6.1. Academic and University Laboratories
8.6.2. Public Health Laboratories
8.6.3. Pharmaceutical and Biotechnology Companies
8.6.4. Contract Research Organizations
8.6.5. Clinical Trial Central Laboratories

What this section provides: This section explains which healthcare and laboratory settings drive specimen collection purchasing and identifies customer groups expected to benefit most from decentralized collection, automation, and patient-centric sampling.

9. U.S. IVD Specimen Collection Devices Market – By Geography

9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Clinical Laboratory Testing and Collection Volume Analysis
9.1.4. Regional Hospital and Reference Laboratory Infrastructure Analysis
9.1.5. Regional Decentralized Collection Adoption Analysis
9.1.6. Regional Procurement, Distribution and GPO Dynamics
9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Key Manufacturers, Laboratories and Procurement Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.8. California
9.2.8.1. Overview
9.2.8.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.8.3. California Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.8.4. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.8.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.9. Washington
9.2.9.1. Overview
9.2.9.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.9.3. Washington Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.9.4. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.9.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.10. Arizona
9.2.10.1. Overview
9.2.10.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.10.3. Arizona Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.10.4. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.10.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.11. Colorado
9.2.11.1. Overview
9.2.11.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.11.3. Colorado Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.11.4. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.11.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.12. Oregon
9.2.12.1. Overview
9.2.12.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.12.3. Oregon Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.12.4. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.12.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.13. Utah
9.2.13.1. Overview
9.2.13.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.13.3. Utah Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.13.4. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.13.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.14. Nevada
9.2.14.1. Overview
9.2.14.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.14.3. Nevada Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.14.4. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.14.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.15. New Mexico
9.2.15.1. Overview
9.2.15.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.15.3. New Mexico Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.15.4. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.15.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.16. Idaho
9.2.16.1. Overview
9.2.16.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.16.3. Idaho Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.16.4. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.16.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.17. Montana
9.2.17.1. Overview
9.2.17.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.17.3. Montana Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.17.4. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.17.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.18. Wyoming
9.2.18.1. Overview
9.2.18.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.18.3. Wyoming Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.18.4. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.18.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.19. Alaska
9.2.19.1. Overview
9.2.19.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.19.3. Alaska Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.19.4. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.19.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.20. Hawaii
9.2.20.1. Overview
9.2.20.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.20.3. Hawaii Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.2.20.4. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.20.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Key Manufacturers, Laboratories and Procurement Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.8. New York
9.3.8.1. Overview
9.3.8.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.8.3. New York Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.8.4. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.8.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.9. Massachusetts
9.3.9.1. Overview
9.3.9.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.9.3. Massachusetts Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.9.4. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.9.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.10. New Jersey
9.3.10.1. Overview
9.3.10.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.10.3. New Jersey Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.10.4. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.10.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.11. Pennsylvania
9.3.11.1. Overview
9.3.11.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.11.3. Pennsylvania Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.11.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.11.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.12. Connecticut
9.3.12.1. Overview
9.3.12.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.12.3. Connecticut Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.12.4. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.12.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.13. Maine
9.3.13.1. Overview
9.3.13.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.13.3. Maine Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.13.4. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.13.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.14. Vermont
9.3.14.1. Overview
9.3.14.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.14.3. Vermont Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.14.4. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.14.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.15. New Hampshire
9.3.15.1. Overview
9.3.15.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.15.3. New Hampshire Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.15.4. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.15.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.16. Rhode Island
9.3.16.1. Overview
9.3.16.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.16.3. Rhode Island Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.16.4. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.16.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.17. Delaware
9.3.17.1. Overview
9.3.17.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.17.3. Delaware Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.3.17.4. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.17.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Key Manufacturers, Laboratories and Procurement Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.8. Texas
9.4.8.1. Overview
9.4.8.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.8.3. Texas Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.8.4. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.8.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.9. Florida
9.4.9.1. Overview
9.4.9.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.9.3. Florida Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.9.4. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.9.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.10. Georgia
9.4.10.1. Overview
9.4.10.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.10.3. Georgia Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.10.4. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.10.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.11. North Carolina
9.4.11.1. Overview
9.4.11.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.11.3. North Carolina Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.11.4. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.11.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.12. Tennessee
9.4.12.1. Overview
9.4.12.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.12.3. Tennessee Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.12.4. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.12.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.13. South Carolina
9.4.13.1. Overview
9.4.13.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.13.3. South Carolina Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.13.4. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.13.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.14. Alabama
9.4.14.1. Overview
9.4.14.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.14.3. Alabama Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.14.4. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.14.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.15. Mississippi
9.4.15.1. Overview
9.4.15.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.15.3. Mississippi Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.15.4. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.15.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.16. Louisiana
9.4.16.1. Overview
9.4.16.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.16.3. Louisiana Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.16.4. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.16.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.17. Arkansas
9.4.17.1. Overview
9.4.17.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.17.3. Arkansas Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.17.4. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.17.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.18. Kentucky
9.4.18.1. Overview
9.4.18.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.18.3. Kentucky Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.18.4. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.18.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.19. Oklahoma
9.4.19.1. Overview
9.4.19.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.19.3. Oklahoma Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.19.4. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.19.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.20. Virginia
9.4.20.1. Overview
9.4.20.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.20.3. Virginia Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.20.4. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.20.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.21. Maryland
9.4.21.1. Overview
9.4.21.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.21.3. Maryland Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.21.4. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.21.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.22. West Virginia
9.4.22.1. Overview
9.4.22.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.22.3. West Virginia Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.4.22.4. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.22.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Key Manufacturers, Laboratories and Procurement Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.8. Illinois
9.5.8.1. Overview
9.5.8.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.8.3. Illinois Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.8.4. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.8.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.9. Ohio
9.5.9.1. Overview
9.5.9.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.9.3. Ohio Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.9.4. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.9.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.10. Michigan
9.5.10.1. Overview
9.5.10.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.10.3. Michigan Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.10.4. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.10.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.11. Minnesota
9.5.11.1. Overview
9.5.11.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.11.3. Minnesota Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.11.4. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.11.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.12. Indiana
9.5.12.1. Overview
9.5.12.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.12.3. Indiana Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.12.4. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.12.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.13. Wisconsin
9.5.13.1. Overview
9.5.13.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.13.3. Wisconsin Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.13.4. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.13.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.14. Missouri
9.5.14.1. Overview
9.5.14.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.14.3. Missouri Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.14.4. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.14.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.15. Iowa
9.5.15.1. Overview
9.5.15.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.15.3. Iowa Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.15.4. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.15.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.16. Kansas
9.5.16.1. Overview
9.5.16.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.16.3. Kansas Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.16.4. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.16.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.17. Nebraska
9.5.17.1. Overview
9.5.17.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.17.3. Nebraska Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.17.4. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.17.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.18. North Dakota
9.5.18.1. Overview
9.5.18.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.18.3. North Dakota Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.18.4. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.18.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.19. South Dakota
9.5.19.1. Overview
9.5.19.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.19.3. South Dakota Market Size and Forecast, By Specimen Type, 2021–2035 (US$ Billion)
9.5.19.4. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.19.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed four-region and all-state analysis, enabling clients to identify priority U.S. geographies, laboratory-testing hubs, hospital and reference laboratory clusters, decentralized collection opportunities, and state-level commercial potential.

10. U.S. IVD Specimen Collection Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking
10.3. Company Positioning Matrix
10.3.1. Leaders
10.3.2. Challengers
10.3.3. Innovators
10.3.4. Emerging Players
10.4. Product Portfolio Benchmarking
10.5. Innovation and Decentralized Collection Positioning
10.6. Company Profiles
10.6.1. Becton, Dickinson and Company
10.6.2. Greiner Bio-One International GmbH
10.6.3. SARSTEDT AG & Co. KG
10.6.4. Cardinal Health, Inc.
10.6.5. Medline Industries, LP
10.6.6. McKesson Corporation
10.6.7. Thermo Fisher Scientific Inc.
10.6.8. COPAN Diagnostics Inc.
10.6.9. Puritan Medical Products
10.6.10. Hardy Diagnostics
10.6.11. QIAGEN N.V.
10.6.12. OraSure Technologies, Inc.
10.6.13. DNA Genotek Inc.
10.6.14. Terumo Medical Corporation
10.6.15. Nipro Medical Corporation
10.6.16. Sol-Millennium Medical Group
10.6.17. Retractable Technologies, Inc.
10.6.18. Owen Mumford Ltd.
10.6.19. Tasso, Inc.
10.6.20. Babson Diagnostics, Inc.
10.6.21. Trajan Scientific and Medical
10.6.22. Neoteryx LLC
10.6.23. Spot On Sciences, Inc.
10.6.24. Mawi DNA Technologies LLC

Note: Each company profile will include company overview, specimen collection product portfolio, U.S. market presence, competitive positioning, distribution strategy, innovation pipeline, regulatory activity, partnerships, strategic initiatives, and recent developments.

What this section provides: This section provides competitor benchmarking, market share visibility, portfolio positioning, innovation intelligence, distribution analysis, and strategic assessment of major conventional and next-generation specimen collection companies.

11. U.S. IVD Specimen Collection Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario
11.2. Disruptive Technologies Impact
11.2.1. Capillary Blood Collection and Microsampling
11.2.2. Patient Self-Collection Technologies
11.2.3. Needle-Free and Peripheral IV Blood Collection
11.2.4. Molecular Specimen Stabilization Technologies
11.2.5. Dried Blood Spot and Volumetric Absorptive Microsampling
11.2.6. Automated Specimen Identification and Tracking
11.2.7. Smart Collection Devices and Digital Traceability
11.3. Future of Home and Decentralized Specimen Collection
11.4. Laboratory Automation and Pre-Analytical Workflow Evolution
11.5. Emerging Business Trends
11.6. Business Opportunities for Startups and Existing Players
11.7. Investment Prioritization Matrix
11.8. Product Category Opportunity Matrix
11.9. State and Regional Expansion Opportunity Matrix

What this section provides: This section prepares clients for future shifts in specimen collection technology, laboratory workflow, decentralized diagnostics, competitive structure, and investment opportunities through 2035.

12. U.S. IVD Specimen Collection Devices Market: Strategic Recommendations

12.1. Recommendations for Specimen Collection Device Manufacturers
12.2. Recommendations for Hospitals and Integrated Health Systems
12.3. Recommendations for Independent and Reference Laboratories
12.4. Recommendations for Investors and Private Equity Firms
12.5. Recommendations for Distributors and Channel Partners
12.6. Recommendations for New Entrants and Startups
12.7. Go-to-Market Strategy Considerations
12.8. Product Positioning and Portfolio Expansion Guidance
12.9. Hospital and Laboratory Contracting Strategy
12.10. Decentralized Collection Commercialization Strategy
12.11. State-Level Market Entry Prioritization
12.12. Partnership, Distribution and Acquisition Opportunities

What this section provides: This section converts the market intelligence into actionable recommendations for product development, portfolio positioning, contracting, distribution, geographic expansion, investment planning, and competitive differentiation.

13. U.S. IVD Specimen Collection Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Data Use Limitation
13.3. Market Definition and Product Inclusion Limitation
13.4. Forecasting Limitation
13.5. Legal Disclaimer
13.6. Third-Party Data Disclaimer
13.7. State-Level Market Estimation Limitation

What this section provides: This section clarifies the report’s scope boundaries, market-sizing limitations, forecasting assumptions, state-level estimation methodology, legal conditions, and data-use limitations.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. IVD Specimen Collection Devices Market: Market Definition and Scope
TABLE 3: U.S. IVD Specimen Collection Devices Market: Research Methodology Framework
TABLE 4: U.S. IVD Specimen Collection Devices Market: Key Assumptions
TABLE 5: U.S. IVD Specimen Collection Devices Market: Market Ecosystem Overview
TABLE 6: U.S. IVD Specimen Collection Devices Market: Stakeholder Analysis
TABLE 7: U.S. IVD Specimen Collection Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. IVD Specimen Collection Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. IVD Specimen Collection Devices Market: Market Attractiveness Index
TABLE 10: U.S. IVD Specimen Collection Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. IVD Specimen Collection Devices Market: Base Year Market Positioning, 2025 (US$ Billion)
TABLE 12: U.S. IVD Specimen Collection Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. IVD Specimen Collection Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. IVD Specimen Collection Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. IVD Specimen Collection Devices Market: Decentralized and Self-Collection Opportunity Assessment
TABLE 16: U.S. IVD Specimen Collection Devices Market: Drivers; Impact Analysis
TABLE 17: U.S. IVD Specimen Collection Devices Market: Restraints; Impact Analysis
TABLE 18: U.S. IVD Specimen Collection Devices Market: Opportunities; Impact Analysis
TABLE 19: U.S. IVD Specimen Collection Devices Market: Challenges; Impact Analysis
TABLE 20: U.S. IVD Specimen Collection Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. IVD Specimen Collection Devices Market: Pre-Analytical Clinical Workflow Economics Matrix
TABLE 22: U.S. IVD Specimen Collection Devices Market: Hospital and Laboratory Procurement Behavior Matrix
TABLE 23: U.S. IVD Specimen Collection Devices Market: Specimen Quality and Laboratory Rejection Economics
TABLE 24: U.S. IVD Specimen Collection Devices Market: Decentralized Testing Impact on Collection Workflows
TABLE 25: U.S. IVD Specimen Collection Devices Market: PESTEL Analysis
TABLE 26: U.S. IVD Specimen Collection Devices Market: Porter’s Five Forces Analysis
TABLE 27: U.S. IVD Specimen Collection Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 28: U.S. IVD Specimen Collection Devices Market: Value Chain Analysis
TABLE 29: U.S. IVD Specimen Collection Devices Market: Supply Chain Analysis
TABLE 30: U.S. IVD Specimen Collection Devices Market: Raw Material and Manufacturing Landscape
TABLE 31: U.S. IVD Specimen Collection Devices Market: Laboratory Automation and Digitalization Impact
TABLE 32: U.S. IVD Specimen Collection Devices Market: Application & Innovation Landscape
TABLE 33: U.S. IVD Specimen Collection Devices Market: FDA Regulatory Framework Analysis
TABLE 34: U.S. IVD Specimen Collection Devices Market: CLIA and Laboratory Quality Framework
TABLE 35: U.S. IVD Specimen Collection Devices Market: CMS Reimbursement and Specimen Collection Payment Landscape
TABLE 36: U.S. IVD Specimen Collection Devices Market: OSHA Sharps Safety and Healthcare Worker Protection Landscape
TABLE 37: U.S. IVD Specimen Collection Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 38: U.S. IVD Specimen Collection Devices Market: Government Initiatives and Public Health Testing Programs
TABLE 39: U.S. IVD Specimen Collection Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 40: U.S. IVD Specimen Collection Devices Market: Hospital and Laboratory Value Analysis Committee Framework
TABLE 41: U.S. IVD Specimen Collection Devices Market: GPO Contracting and Vendor Standardization Analysis
TABLE 42: U.S. IVD Specimen Collection Devices Market: Product Type Snapshot, 2025
TABLE 43: Segment Dashboard; Definition and Scope, by Product Type
TABLE 44: U.S. IVD Specimen Collection Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 45: U.S. IVD Specimen Collection Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 46: U.S. IVD Specimen Collection Devices Market: Blood Collection Tubes and Microcollection Containers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. IVD Specimen Collection Devices Market: Needles, Blood Collection Sets, Holders and Lancets Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. IVD Specimen Collection Devices Market: Swabs and Microbiological Collection Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. IVD Specimen Collection Devices Market: Urine, Stool, Saliva and Other Specimen Containers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. IVD Specimen Collection Devices Market: Transport, Stabilization, Collection Cards and Specialty Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. IVD Specimen Collection Devices Market: Specimen Type Snapshot, 2025
TABLE 52: Segment Dashboard; Definition and Scope, by Specimen Type
TABLE 53: U.S. IVD Specimen Collection Devices Market, by Specimen Type, 2021–2035 (US$ Billion)
TABLE 54: U.S. IVD Specimen Collection Devices Market: Segment Share Analysis, by Specimen Type, 2025 & 2035 (%)
TABLE 55: U.S. IVD Specimen Collection Devices Market: Blood Specimens Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. IVD Specimen Collection Devices Market: Respiratory Specimens Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. IVD Specimen Collection Devices Market: Urine Specimens Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. IVD Specimen Collection Devices Market: Stool Specimens Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. IVD Specimen Collection Devices Market: Saliva, Buccal, Genital and Other Specialty Specimens Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. IVD Specimen Collection Devices Market: Application Snapshot, 2025
TABLE 61: Segment Dashboard; Definition and Scope, by Application
TABLE 62: U.S. IVD Specimen Collection Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 63: U.S. IVD Specimen Collection Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 64: U.S. IVD Specimen Collection Devices Market: Routine Clinical Chemistry, Hematology and Coagulation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. IVD Specimen Collection Devices Market: Infectious Disease and Microbiology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. IVD Specimen Collection Devices Market: Chronic Disease Screening and Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. IVD Specimen Collection Devices Market: Oncology, Genomic and Molecular Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. IVD Specimen Collection Devices Market: Women’s Health, Reproductive Health, Toxicology and Specialty Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. IVD Specimen Collection Devices Market: End User Snapshot, 2025
TABLE 70: Segment Dashboard; Definition and Scope, by End User
TABLE 71: U.S. IVD Specimen Collection Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 72: U.S. IVD Specimen Collection Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 73: U.S. IVD Specimen Collection Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. IVD Specimen Collection Devices Market: Independent and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. IVD Specimen Collection Devices Market: Physician Offices, Urgent Care Centers and Outpatient Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. IVD Specimen Collection Devices Market: Retail, Home Health, Mobile and Decentralized Collection Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. IVD Specimen Collection Devices Market: Academic, Public Health, Pharmaceutical and Research Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. IVD Specimen Collection Devices Market: Regional Snapshot, 2025
TABLE 79: Segment Dashboard; Definition and Scope, by Geography
TABLE 80: U.S. IVD Specimen Collection Devices Market, by Geography, 2021–2035 (US$ Billion)
TABLE 81: U.S. IVD Specimen Collection Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 82: U.S. IVD Specimen Collection Devices Market: Regional Clinical Laboratory Testing and Collection Volume Analysis
TABLE 83: U.S. IVD Specimen Collection Devices Market: Regional Hospital and Reference Laboratory Infrastructure Analysis
TABLE 84: U.S. IVD Specimen Collection Devices Market: Regional Decentralized Collection Adoption Analysis
TABLE 85: U.S. IVD Specimen Collection Devices Market: Regional Procurement, Distribution and GPO Dynamics
TABLE 86: West Region U.S. IVD Specimen Collection Devices Market: Regional Overview and Trends
TABLE 87: West Region U.S. IVD Specimen Collection Devices Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 88: West Region U.S. IVD Specimen Collection Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 89: West Region U.S. IVD Specimen Collection Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 90: West Region U.S. IVD Specimen Collection Devices Market, by Specimen Type, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. IVD Specimen Collection Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. IVD Specimen Collection Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 93: California IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Washington IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: Arizona IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Colorado IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Oregon IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Utah IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Nevada IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: New Mexico IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Idaho IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Montana IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Wyoming IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Alaska IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Hawaii IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Northeast Region U.S. IVD Specimen Collection Devices Market: Regional Overview and Trends
TABLE 107: Northeast Region U.S. IVD Specimen Collection Devices Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 108: Northeast Region U.S. IVD Specimen Collection Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. IVD Specimen Collection Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 110: Northeast Region U.S. IVD Specimen Collection Devices Market, by Specimen Type, 2021–2035 (US$ Billion)
TABLE 111: Northeast Region U.S. IVD Specimen Collection Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. IVD Specimen Collection Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 113: New York IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Massachusetts IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: New Jersey IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Pennsylvania IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Connecticut IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Maine IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Vermont IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: New Hampshire IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Rhode Island IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Delaware IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: South Region U.S. IVD Specimen Collection Devices Market: Regional Overview and Trends
TABLE 124: South Region U.S. IVD Specimen Collection Devices Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 125: South Region U.S. IVD Specimen Collection Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. IVD Specimen Collection Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 127: South Region U.S. IVD Specimen Collection Devices Market, by Specimen Type, 2021–2035 (US$ Billion)
TABLE 128: South Region U.S. IVD Specimen Collection Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. IVD Specimen Collection Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 130: Texas IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Florida IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Georgia IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: North Carolina IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Tennessee IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: South Carolina IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Alabama IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Mississippi IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Louisiana IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Arkansas IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Kentucky IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Oklahoma IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Virginia IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Maryland IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: West Virginia IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Midwest Region U.S. IVD Specimen Collection Devices Market: Regional Overview and Trends
TABLE 146: Midwest Region U.S. IVD Specimen Collection Devices Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 147: Midwest Region U.S. IVD Specimen Collection Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region U.S. IVD Specimen Collection Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 149: Midwest Region U.S. IVD Specimen Collection Devices Market, by Specimen Type, 2021–2035 (US$ Billion)
TABLE 150: Midwest Region U.S. IVD Specimen Collection Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 151: Midwest Region U.S. IVD Specimen Collection Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 152: Illinois IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Ohio IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Michigan IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Minnesota IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Indiana IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Wisconsin IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Missouri IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Iowa IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Kansas IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Nebraska IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: North Dakota IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: South Dakota IVD Specimen Collection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: U.S. IVD Specimen Collection Devices Market: Competitive Landscape Snapshot, 2025
TABLE 165: U.S. IVD Specimen Collection Devices Market: Key Company Market Share Analysis, 2025
TABLE 166: U.S. IVD Specimen Collection Devices Market: Company Positioning Matrix
TABLE 167: U.S. IVD Specimen Collection Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 168: U.S. IVD Specimen Collection Devices Market: Innovation and Decentralized Collection Positioning
TABLE 169: U.S. IVD Specimen Collection Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 170: Becton, Dickinson and Company: Company Profile
TABLE 171: Greiner Bio-One International GmbH: Company Profile
TABLE 172: SARSTEDT AG & Co. KG: Company Profile
TABLE 173: Cardinal Health, Inc.: Company Profile
TABLE 174: Medline Industries, LP: Company Profile
TABLE 175: McKesson Corporation: Company Profile
TABLE 176: Thermo Fisher Scientific Inc.: Company Profile
TABLE 177: COPAN Diagnostics Inc.: Company Profile
TABLE 178: Puritan Medical Products: Company Profile
TABLE 179: Hardy Diagnostics: Company Profile
TABLE 180: QIAGEN N.V.: Company Profile
TABLE 181: OraSure Technologies, Inc.: Company Profile
TABLE 182: DNA Genotek Inc.: Company Profile
TABLE 183: Terumo Medical Corporation: Company Profile
TABLE 184: Nipro Medical Corporation: Company Profile
TABLE 185: Sol-Millennium Medical Group: Company Profile
TABLE 186: Retractable Technologies, Inc.: Company Profile
TABLE 187: Owen Mumford Ltd.: Company Profile
TABLE 188: Tasso, Inc.: Company Profile
TABLE 189: Babson Diagnostics, Inc.: Company Profile
TABLE 190: Trajan Scientific and Medical: Company Profile
TABLE 191: Neoteryx LLC: Company Profile
TABLE 192: Spot On Sciences, Inc.: Company Profile
TABLE 193: Mawi DNA Technologies LLC: Company Profile
TABLE 194: U.S. IVD Specimen Collection Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 195: U.S. IVD Specimen Collection Devices Market: Disruptive Technologies Impact Matrix
TABLE 196: U.S. IVD Specimen Collection Devices Market: Capillary Blood Collection and Microsampling Opportunity
TABLE 197: U.S. IVD Specimen Collection Devices Market: Patient Self-Collection Technology Opportunity
TABLE 198: U.S. IVD Specimen Collection Devices Market: Needle-Free and Peripheral IV Blood Collection Opportunity
TABLE 199: U.S. IVD Specimen Collection Devices Market: Molecular Specimen Stabilization Opportunity
TABLE 200: U.S. IVD Specimen Collection Devices Market: Home and Decentralized Specimen Collection Outlook
TABLE 201: U.S. IVD Specimen Collection Devices Market: Laboratory Automation and Pre-Analytical Workflow Evolution
TABLE 202: U.S. IVD Specimen Collection Devices Market: Emerging Business Trends
TABLE 203: U.S. IVD Specimen Collection Devices Market: Business Opportunities for Startups and Existing Players
TABLE 204: U.S. IVD Specimen Collection Devices Market: Investment Prioritization Matrix
TABLE 205: U.S. IVD Specimen Collection Devices Market: Product Category Opportunity Matrix
TABLE 206: U.S. IVD Specimen Collection Devices Market: State and Regional Expansion Opportunity Matrix
TABLE 207: U.S. IVD Specimen Collection Devices Market: Strategic Recommendations for Specimen Collection Device Manufacturers
TABLE 208: U.S. IVD Specimen Collection Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 209: U.S. IVD Specimen Collection Devices Market: Strategic Recommendations for Independent and Reference Laboratories
TABLE 210: U.S. IVD Specimen Collection Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 211: U.S. IVD Specimen Collection Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 212: U.S. IVD Specimen Collection Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 213: U.S. IVD Specimen Collection Devices Market: Go-to-Market Strategy Considerations
TABLE 214: U.S. IVD Specimen Collection Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 215: U.S. IVD Specimen Collection Devices Market: Hospital and Laboratory Contracting Strategy
TABLE 216: U.S. IVD Specimen Collection Devices Market: Decentralized Collection Commercialization Strategy
TABLE 217: U.S. IVD Specimen Collection Devices Market: State-Level Market Entry Prioritization
TABLE 218: U.S. IVD Specimen Collection Devices Market: Partnership, Distribution and Acquisition Opportunities
TABLE 219: U.S. IVD Specimen Collection Devices Market: Scope Limitation
TABLE 220: U.S. IVD Specimen Collection Devices Market: Data Use Limitation
TABLE 221: U.S. IVD Specimen Collection Devices Market: Market Definition and Product Inclusion Limitation
TABLE 222: U.S. IVD Specimen Collection Devices Market: Forecasting Limitation
TABLE 223: U.S. IVD Specimen Collection Devices Market: Legal Disclaimer
TABLE 224: U.S. IVD Specimen Collection Devices Market: Third-Party Data Disclaimer
TABLE 225: U.S. IVD Specimen Collection Devices Market: State-Level Market Estimation Limitation

List of Figures

FIGURE 1: U.S. IVD Specimen Collection Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Map
FIGURE 4: Value Chain Analysis
FIGURE 5: Supply Chain Analysis
FIGURE 6: PESTEL Analysis
FIGURE 7: Porter’s Five Forces Analysis
FIGURE 8: Market Attractiveness Analysis
FIGURE 9: Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Pre-Analytical Clinical Workflow Economics Framework
FIGURE 12: Hospital and Laboratory Procurement Decision Framework
FIGURE 13: U.S. IVD Specimen Collection Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 14: U.S. IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 15: U.S. IVD Specimen Collection Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 16: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 17: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Blood Collection Tubes and Microcollection Containers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Needles, Blood Collection Sets, Holders and Lancets Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Swabs and Microbiological Collection Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Urine, Stool, Saliva and Other Specimen Containers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Transport, Stabilization, Collection Cards and Specialty Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Specimen Type Segment Market Share Analysis, 2025 & 2035
FIGURE 24: Specimen Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Blood Specimens Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Respiratory Specimens Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Urine Specimens Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Stool Specimens Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Saliva, Buccal, Genital and Other Specialty Specimens Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 31: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Routine Clinical Chemistry, Hematology and Coagulation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Infectious Disease and Microbiology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Chronic Disease Screening and Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Oncology, Genomic and Molecular Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Women’s Health, Reproductive Health, Toxicology and Specialty Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 38: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Independent and Reference Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Physician Offices, Urgent Care Centers and Outpatient Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Retail, Home Health, Mobile and Decentralized Collection Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Academic, Public Health, Pharmaceutical and Research Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 45: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: West Region U.S. IVD Specimen Collection Devices Market Share and Leading Players, 2025
FIGURE 47: West Region Market Share Analysis by State, 2025
FIGURE 48: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: California IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Washington IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Arizona IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Colorado IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Oregon IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Utah IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Nevada IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: New Mexico IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Idaho IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Montana IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Wyoming IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Alaska IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Hawaii IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Northeast Region U.S. IVD Specimen Collection Devices Market Share and Leading Players, 2025
FIGURE 63: Northeast Region Market Share Analysis by State, 2025
FIGURE 64: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: New York IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Massachusetts IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: New Jersey IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Pennsylvania IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Connecticut IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Maine IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Vermont IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: New Hampshire IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Rhode Island IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Delaware IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: South Region U.S. IVD Specimen Collection Devices Market Share and Leading Players, 2025
FIGURE 76: South Region Market Share Analysis by State, 2025
FIGURE 77: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Texas IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Florida IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Georgia IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: North Carolina IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Tennessee IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: South Carolina IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Alabama IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Mississippi IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Louisiana IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Arkansas IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Kentucky IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Oklahoma IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Virginia IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Maryland IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: West Virginia IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Midwest Region U.S. IVD Specimen Collection Devices Market Share and Leading Players, 2025
FIGURE 94: Midwest Region Market Share Analysis by State, 2025
FIGURE 95: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Illinois IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Ohio IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Michigan IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Minnesota IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Indiana IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Wisconsin IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Missouri IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Iowa IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Kansas IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Nebraska IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: North Dakota IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: South Dakota IVD Specimen Collection Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 109: Company Positioning Matrix
FIGURE 110: Key Player Product Portfolio Benchmarking
FIGURE 111: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 112: IVD Specimen Collection Devices Innovation Roadmap
FIGURE 113: Capillary Blood Collection and Microsampling Adoption Roadmap
FIGURE 114: Patient Self-Collection Opportunity Map
FIGURE 115: Needle-Free Blood Collection Technology Roadmap
FIGURE 116: Molecular Specimen Stabilization Growth Roadmap
FIGURE 117: Home and Decentralized Specimen Collection Growth Roadmap
FIGURE 118: Future Market Scenario Analysis, 2026–2035
FIGURE 119: Disruptive Technologies Impact Matrix
FIGURE 120: Emerging Business Trends Matrix
FIGURE 121: Investment Prioritization Matrix
FIGURE 122: Product Category Opportunity Matrix
FIGURE 123: State and Regional Expansion Opportunity Matrix
FIGURE 124: Strategic Growth Roadmap for U.S. IVD Specimen Collection Device Companies
FIGURE 125: Go-to-Market Strategy Framework
FIGURE 126: Product Positioning and Portfolio Expansion Framework
FIGURE 127: Report Scope and Disclaimer Framework